Shanliang Hu

Yantai, 264000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Multi-regional radiomics based on planning CT and information complementarity between GTVp and GTVn: an explainable model for predicting 5-year recurrence risk in HPV-positive oropharyngeal cancer.

Multi-regional radiomics based on planning CT and information complementarity between GTVp and GTVn: an explainable model for predicting 5-year recurrence risk in HPV-positive oropharyngeal cancer.

Journal: Radiation oncology (London, England)

Published: April 06, 2026

Capturing "source" and "evolution": A 5-year recurrence risk prediction model for nasopharyngeal carcinoma based on integrated radiomic spatial heterogeneity of primary tumor and lymph nodes.

Capturing "source" and "evolution": A 5-year recurrence risk prediction model for nasopharyngeal carcinoma based on integrated radiomic spatial heterogeneity of primary tumor and lymph nodes.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 02, 2026

Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort.

Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort.

Journal: International journal of cancer

Published: September 05, 2025

Metagenomics-Metabolomics Reveals the Alleviation of Indole-3-Ethanol on Radiation-Induced Enteritis in Mice.

Metagenomics-Metabolomics Reveals the Alleviation of Indole-3-Ethanol on Radiation-Induced Enteritis in Mice.

Journal: Journal of microbiology and biotechnology

Published: February 22, 2025

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer.

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer.

Journal: Technology in cancer research & treatment

Published: January 31, 2025

Development and validation of a prognostic nomogram model in locally advanced NSCLC based on metabolic features of PET/CT and hematological inflammatory indicators.

Development and validation of a prognostic nomogram model in locally advanced NSCLC based on metabolic features of PET/CT and hematological inflammatory indicators.

Journal: EJNMMI physics

Published: November 10, 2023

Alginate oligosaccharide ameliorates azithromycin-induced gut microbiota disorder via Bacteroides acidifaciens-FAHFAs and Bacteroides-TCA cycle axes.

Alginate oligosaccharide ameliorates azithromycin-induced gut microbiota disorder via Bacteroides acidifaciens-FAHFAs and Bacteroides-TCA cycle axes.

Journal: Food & function

Published: December 14, 2022

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.

Journal: The oncologist

Published: September 19, 2022

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Journal: Frontiers in oncology

Published: July 21, 2022

C-phycocyanin alleviated cisplatin-induced oxidative stress and inflammation via gut microbiota-metabolites axis in mice.

C-phycocyanin alleviated cisplatin-induced oxidative stress and inflammation via gut microbiota-metabolites axis in mice.

Journal: Frontiers in nutrition

Published: July 18, 2022

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Journal: Frontiers in pharmacology

Published: July 05, 2022

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 14, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026